UCB has announced significant findings from its phase 3b trial of Bimzelx, demonstrating its efficacy in treating psoriatic arthritis compared to AbbVie’s Skyrizi. In this head-to-head study, 49% of patients receiving Bimzelx experienced a reduction in disease activity at Week 16, surpassing the 38% response rate observed in the Skyrizi cohort. This statistically significant outcome reinforces Bimzelx’s potential as a competitive treatment option in this therapeutic area.
The implications of these results are substantial for UCB as it seeks to expand its footprint in the immunology market. With increasing competition in the biologics space, the positive data not only enhances Bimzelx’s market positioning but also strengthens UCB’s overall portfolio strategy. As healthcare providers and payers evaluate treatment options, these findings may influence prescribing patterns and patient access, ultimately shaping the landscape of psoriatic arthritis management.
Start your 7-day trial and see what the database can do →
